rs10236906 HDAC9: better peginterferon response
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- This variant is linked to improved response to peginterferon alfa-2a for chronic hepatitis B
- The effect size is 1.75 and the p value is 8e-6 based on about one thousand individuals
- It is a rare association in the GWAS catalog
Key takeaways
- This variant is linked to improved response to peginterferon alfa-2a for chronic hepatitis B
- The effect size is 1.75 and the p value is 8e-6 based on about one thousand individuals
- It is a rare association in the GWAS catalog
What the research says This variant is associated with peginterferon alfa-2a treatment response in chronic hepatitis B infection[PMID 30972912]. The reported effect size is 1.75 and the p value is 8e-6 based on about one thousand individuals[PMID 30972912].
Reported associations
- Peginterferon alfa-2a treatment response this variant improves response with an effect size of 1.75 p=8e-6 [PMID 30972912]. Evidence quality The GWAS catalog study includes about one thousand individuals and reports a significant association with the variant using an effect size of 1.75 p=8e-6[PMID 30972912]. The evidence is limited to this single case report and no replication data are provided.
No lifestyle considerations on file for this variant.
Frequently asked questions
What does rs10236906 mean?
rs10236906 is a genetic change at the HDAC9 gene that has been linked to better response to peginterferon alfa-2a treatment for chronic hepatitis B.
Is this variant common or rare?
The GWAS catalog reports it as a rare association in about one thousand people.
Can I change my treatment because of this?
No the evidence does not support changing treatment based on this single genetic finding.